Navigation Links
ADVENTRX Reports Third Quarter Financial Results
Date:11/8/2010

Financial ResultsADVENTRX's net loss applicable to common stock for the nine months ended September 30, 2010 was $11.8 million, or $0.94 per share, compared to net loss applicable to common stock of $9.7 million, or $2.40 per share, for the same period in 2009. Included in net loss applicable to common stock for the nine months ended September 30, 2010 and 2009 were non-cash, deemed dividend expenses of approximately $5.6 million and $1.6 million, respectively, related to the Company's January and May 2010 and June, July and August 2009 equity financings.  

R&D expenses for the nine months ended September 30, 2010 were $2.8 million, a decrease of $1.8 million, or 39%, compared to $4.5 million for the same period in 2009.  The decrease was due primarily to a $0.6 million decrease in external bioequivalence/clinical trial study fees and expenses largely attributable the completion of patient enrollment in the ANX-514 bioequivalence study and the completion of ANX-510 studies in the first quarter of 2009, a $0.6 million decrease in personnel costs attributable to lower headcount and the absence of severance costs in 2010, and a $0.5 million decrease in external nonclinical study fees and expenses largely attributable to a decrease in research-related manufacturing expenses for Exelbine.  

SG&A expenses for the nine months ended September 30, 2010 were $3.4 million, a decrease of $0.3 million, or 9%, compared to $3.7 million for the same period in 2009.  The decrease was due primarily to a $0.4 million decrease in fees for professional legal, audit and tax services, a $0.3 million decrease in personnel costs attributable to lower headcount and the absence of severance costs in 2010, and a $0.1 million decrease in the cost of the Company's facilities lease, partially offset by a $0.3 million increase in director compensation and stock compensation expense and a $0.2 million increase in fees for accounting, investor relations and
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 STAAR Surgical Company (NASDAQ: ... marketer of minimally invasive ophthalmic products, today announced that ... review the Company,s recent financial results and business developments ... will present at the 38 th Annual Deutsche ... at the Westin Waterfront Hotel on Wednesday, May ...
(Date:5/20/2013)... GENEVA , May 21, 2013 ... Health Assembly, where world,s health ministers gather to address ... Mental and neurological disorders (MNDs) affect 700 ... global non-communicable disease (NCD) burden ,Do You ... understand the role each can play to collectively address ...
(Date:5/20/2013)... Landauer, Inc. (NYSE: LDR ), ... and monitoring, outsourced medical physics services and high quality ... Directors declared, at its meeting on May 16, 2013, ... for the third quarter of fiscal 2013.  The dividend ... of record on June 7, 2013. About ...
Breaking Medicine Technology:STAAR Surgical To Present At Upcoming Investor Conferences 2Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign to Fight Mental and Neurological Disorders 2Landauer, Inc. Declares Regular Cash Dividend 2
... March 8, 2012 , Quality of Life ... available treatment fails in two thirds of patients ... Pevion Biotech AG today announced results from a large, ... vulvovaginal candidiasis (RVVC) patients. It is the first time that ...
... Inc. (Nasdaq: BIOD ) today announced that ... will present a corporate update at the ROTH 24th Annual ... 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). ... Conference will be held March 11-14, 2012, at the ...
Cached Medicine Technology:Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 2Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 3Pevion Mandated Patient Survey Confirms Disease Burden of Recurrent Vulvovaginal Candidiasis (RVVC) and Indicates Public Health Problem 4
(Date:5/21/2013)... significantly more likely than their normal-weight counterparts to ... disrupts continuity of care and leads to more ... , The practice of "doctor shopping" among overweight ... with the health care system, whether that be ... advice by providers, or improperly sized medical equipment ...
(Date:5/21/2013)... Children using the abutment-free implantable bone ... results comparable to the traditionally used, competitive abutment ... to a new study. , “The results are ... performs just as well as technology with a ... says Jim Kasic, president and CEO of Sophono. ...
(Date:5/21/2013)... News) -- Urban elementary school children with poorly ... and suffer academically, new research indicates. "In ... nine, we found that compromised lung function corresponded ... performance," said study author Daphne Koinis-Mitchell, an ... Brown University,s Alpert Medical School in Providence, R.I. ...
(Date:5/21/2013)... nanoparticles are usually toxic to cells, but cancer ... Clinic researchers found out why, and determined how ... cells. The discovery is detailed in the current ... Chemistry ., "This study identifies a novel mechanism ... cell death or apoptosis which should occur when ...
(Date:5/21/2013)... Representatives with Hammerhead Bicycles announced today that ... the company has achieved its overall goal of becoming a ... to move Hammerhead Bicycles from a house brand to a ... , Robertson explained that the bike shop will go forward ... on all things 29er and 650b. , “The ...
Breaking Medicine News(10 mins):Health News:'Doctor shopping' by obese patients negatively affects health 2Health News:'Doctor shopping' by obese patients negatively affects health 3Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 2Health News:Abutment-Free Sophono Systems Produce Comparable Study Results to Cochlear’s Baha Products, With Fewer Complications 3Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2Health News:Mayo Clinic: How gold nanoparticles can help fight ovarian cancer 2Health News:Hammerhead Bicycles Now a Standalone Brand 2
... Medical Record/Practice Management Software Company Aimed at Giving ... HILLS, Mich., May 27 gloStream, a healthcare ... Office embedded electronic medical record ("EMR") and practice ... closed on a $7.5 million series B financing ...
... When Chicago Blackhawk,s leading scorer Martin Havlat returned ... Conference Final after sustaining a concussion only two days ... to a new study by St. Michael,s Hospital neurosurgeon ... of minor league hockey players who did not know ...
... to healthier livesST. LOUIS, May 27 Nurse Response ... new consumer health tool that will complement the quality ... Response will offer the Healthwise Knowledgebase, an online consumer ... to access over 7,000 health topics online. , ...
... York, NY / Los Angeles, CA: Stand Up ... aimed at getting new cancer treatments to patients in ... the first round of three-year grants that total ... Teams. The majority of these funds were raised in ...
... The Institute for Palliative Medicine plays unique roleSAN DIEGO, ... Irwin, M.D., Ph.D., Director of the Palliative Care Psychiatry ... been elected as a Member of The American College ... one of only 750 practicing psychiatrists nationwide who have ...
... for stricter regulatory approval requirements and continuity of product supply. ... ... A recent report released by Wolters Kluwer Health predicts that by ... will be filled with generic drugs. This march to generics ...
Cached Medicine News:Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 2Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 3Health News:gloStream Announces $7.5 Million Series B Financing Round Co-Led by Beringea and gloStream's Executive Management Team 4Health News:Minor league hockey players unable to identify concussion symptoms, study says 2Health News:Minor league hockey players unable to identify concussion symptoms, study says 3Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 2Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 3Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 4Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 5Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 6Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 7Health News:Stand Up to Cancer awards $73.6 million for novel, groundbreaking cancer research 8Health News:San Diego Psychiatrist Scott Irwin Honored With National Recognition 2Health News:San Diego Psychiatrist Scott Irwin Honored With National Recognition 3Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 2Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 3Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 4Health News:In the Case of Epilepsy, Generic Drugs and Random Product Substitution are Not Always "Good Medicine" 5
The most compact revolutionary innovation in hematology. 3 Part DIFF + CRP measurement on whole blood....
... Evolis™ is a self contained microplate ... based EIA assays. The system is dedicated ... encountered in todays busy laboratory. The system ... of EIA assays that satisfy their microplate ...
... Retrieval System is made up of three ... Microcatheter and the Merci Balloon Guide Catheter. ... the location of the clot has been ... Catheter is inserted through a small incision ...
... 3080/3085 SP Bariatric Foot Extension provides extraordinary ... surgical capabilities for Amsco 3080 and 3085 ... Extension is rated for patients up to ... and easy attachment and full positioning capability. ...
Medicine Products: